Tirzepatide in PWS, HO and GNSO

NCT06901245

Status	RECRUITING
Phase	Phase 4
Sponsor	Grace Kim
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (7)

- Individuals 18-26 years with a BMI in the obesity range (BMI e95th percentile for age and sex or e30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
- In a stable care setting at least 6 months prior to enrollment
- Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan.
- Ability to take weekly subcutaneous tirzepatide
- Consistent caregiver if they are not independent

... and 2 more (see full listing online)

Exclusion (20)

- Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
- Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
- Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
- Any medications that may affect the study endpoints
- Significant weight change (\>3% weight gain or loss) in the last 2 months prior to enrollment

... and 15 more (see full listing online)

Locations (3 total)

Children's Minnesota, Saint Paul, Minnesota, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Seattle Children's Hospital, Seattle, Washington, United States